JP2025508840A5 - - Google Patents
Info
- Publication number
- JP2025508840A5 JP2025508840A5 JP2024550216A JP2024550216A JP2025508840A5 JP 2025508840 A5 JP2025508840 A5 JP 2025508840A5 JP 2024550216 A JP2024550216 A JP 2024550216A JP 2024550216 A JP2024550216 A JP 2024550216A JP 2025508840 A5 JP2025508840 A5 JP 2025508840A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- polypeptide
- arg2
- polypeptide according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2202547.2A GB202202547D0 (en) | 2022-02-24 | 2022-02-24 | Arginase 2 vaccine |
| GB2202547.2 | 2022-02-24 | ||
| GBGB2213372.2A GB202213372D0 (en) | 2022-09-13 | 2022-09-13 | Arginase 2 vaccine |
| GB2213372.2 | 2022-09-13 | ||
| PCT/EP2023/054568 WO2023161346A1 (en) | 2022-02-24 | 2023-02-23 | Arginase 2 vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508840A JP2025508840A (ja) | 2025-04-10 |
| JP2025508840A5 true JP2025508840A5 (cg-RX-API-DMAC7.html) | 2026-03-04 |
Family
ID=85415242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024550216A Pending JP2025508840A (ja) | 2022-02-24 | 2023-02-23 | アルギナーゼ2ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250161422A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4482518A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025508840A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240159833A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119110729A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023223567A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3250919A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315164A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023161346A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| PL3522905T3 (pl) | 2016-10-07 | 2025-01-07 | Io Biotech Aps | Immunogenne peptydy arginazowe |
| AU2019201463A1 (en) * | 2018-03-09 | 2019-09-26 | Nantomics, Llc | Srm/mrm assays for profiling tumor tissue |
| GB201815549D0 (en) | 2018-09-24 | 2018-11-07 | Io Biotech Aps | Arginase1 polypeptides |
| US20210382068A1 (en) * | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| GB201818576D0 (en) | 2018-11-14 | 2018-12-26 | Io Biotech Aps | Arginase 2 polypeptides |
-
2023
- 2023-02-23 US US18/841,338 patent/US20250161422A1/en active Pending
- 2023-02-23 IL IL315164A patent/IL315164A/en unknown
- 2023-02-23 CA CA3250919A patent/CA3250919A1/en active Pending
- 2023-02-23 JP JP2024550216A patent/JP2025508840A/ja active Pending
- 2023-02-23 CN CN202380023567.8A patent/CN119110729A/zh active Pending
- 2023-02-23 KR KR1020247031949A patent/KR20240159833A/ko active Pending
- 2023-02-23 AU AU2023223567A patent/AU2023223567A1/en active Pending
- 2023-02-23 WO PCT/EP2023/054568 patent/WO2023161346A1/en not_active Ceased
- 2023-02-23 EP EP23708178.1A patent/EP4482518A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | The roles of tissue resident macrophages in health and cancer | |
| Nowak et al. | New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents | |
| US6328956B1 (en) | Pharmaceutical composition for the treatment or prevention of a malignant tumor | |
| JP2022095926A (ja) | 乳癌再発の予防のためのワクチン | |
| Oki et al. | Heat shock protein-based cancer vaccines | |
| Taniura et al. | Immunogenic chemotherapy in two mouse colon cancer models | |
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| He et al. | CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo | |
| CN111154806A (zh) | 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用 | |
| Younes et al. | Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity | |
| CN115702927A (zh) | 一种广谱性肿瘤疫苗增效的组合物 | |
| Toda | Glioma stem cells and immunotherapy for the treatment of malignant gliomas | |
| JPH09511737A (ja) | 免疫治療剤とその使用 | |
| Yang et al. | Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant | |
| JP2022507373A5 (cg-RX-API-DMAC7.html) | ||
| WO2017177908A1 (zh) | Pd-l1和pd-l2重组蛋白及其用途 | |
| Boliukh et al. | Immunological aspects of heat shock protein functions and their significance in the development of cancer vaccines | |
| AU725218B2 (en) | Immunogenic TLP composition | |
| MX2007006717A (es) | Peptidos de alfa timocina como adyuvantes en vacunas contra el cancer. | |
| di Pietro et al. | Oncophage®(vitespen®)-Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get? | |
| He et al. | Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2 | |
| EP0466813A1 (en) | Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins | |
| CN112402612B (zh) | 一种提高肿瘤新抗原疫苗免疫治疗疗效的方法 | |
| Nemunaitis et al. | 630. A phase 2 randomized study of GM-CSF gene-modified autologous tumor cell immunotherapy (CG8123) with and without low-dose cyclophosphamide in advanced stage non-small cell lung cancer (NSCLC) | |
| Niu | Locally Administered Particle-Anchored Cytokines Safely Enhance Cancer Immunotherapy |